Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 22nd January 2020
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New guidelines on the safe use of analgesia in horses
Animal welfare can be significantly affected by pain.
Recommendations aimed at equine primary care in an ambulatory setting

Clinical guidelines for primary care vets on the safe use of analgesia in horses have been published in the January issue of the Equine Veterinary Journal (EVJ).

The guidelines have been produced by the British Equine Veterinary Association (BEVA) and can be downloaded at https://beva.onlinelibrary.wiley.com/doi/10.1111/evj.13198

In human medicine, clinical guidelines are standard practice and have proven to influence clinical decision making in clinical settings. BEVA’s set of clinical guidelines are the first to be aimed at equine primary care in an ambulatory setting.

Animal wefare can be significantly affected by pain and analgesia is considered to be key in helping to alleviate it. Put together by a panel combining clinicians and analgesia researchers, the guidelines summarise current evidence and combine it with expert opinion to provide best practice advice on common scenarios.

Key recommendations include:
  • Horses undergoing routine castration should receive intratesticular local anaesthesia irrespective of methods adopted and horses should receive NSAIDs before surgery. Butorphanol and buprenorphine should not be considered appropriate as sole analgesics for such procedures and analgesia should be continued for three days following castration.
  • For hoof pain/laminitis phenylbutazone provided superior analgesia to meloxicam and firocoxib but enhanced efficacy has not been demonstrated for joint pain.
  • In horses with colic, flunixin and firocoxib are considered to provide more effective analgesia than meloxicam or phenylbutazone.
  • A single properly validated composite pain score for horses should be developed, to allow accurate comparisons between medications in a robust manner.
“Given the risk of adverse events of all classes of analgesic, these agents should be used only under the control of a veterinary surgeon,” explained Professor Mark Bowen, lead author of the guidelines. “The horse must have been fully evaluated and the vet must have devised a therapeutic, analgesic plan that includes ongoing monitoring for such adverse events such as the development of right dorsal colitis with all classes of NSAID and spontaneous locomotor activity and potentially ileus with opiates.”

EVJ editor Professor Celia Marr added: “The BEVA primary care clinical guidelines provide up-to-date clarity on the fundamental aspects of equine pain management for the clinician and are essential reading for all those in first opinion ambulatory roles.”

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.